News & Comment

Filter By:

Article Type
Year

  • In a land where drugs for ultra-rare indications are the new blockbusters, Alexion's Soliris is king.

    • Brady Huggett
    Case Study

  • Compared with the long time horizons and diminished returns of traditional antibody startups, Ablexis gave investors a deal they couldn't refuse.

    • Christopher Scott
    Case Study